Combination of MnSOD, CAT, and GPX1 genetic polymorphisms and risk of prostate cancer in Caucasian
| Number of risk alleles* . | Cases . | Controls . | Crude OR (95% CI) . | OR (95% CI)† . | ||||
|---|---|---|---|---|---|---|---|---|
| 0 | 31 (7.4) | 85 (7.6) | 1.0 (ref) | 1.0 (ref) | ||||
| 1 | 117 (28.1) | 287 (25.7) | 1.1 (0.70-1.78) | 1.1 (0.69-1.85) | ||||
| 2 | 140 (33.6) | 368 (33.0) | 1.0 (0.66-1.64) | 1.0 (0.59-1.56) | ||||
| 3 | 87 (20.9) | 274 (24.5) | 0.9 (0.54-1.40) | 0.8 (0.51-1.41) | ||||
| 4 | 30 (7.2) | 86 (7.7) | 1.0 (0.53-1.72) | 1.0 (0.52-1.81) | ||||
| ≥5 | 12 (2.8) | 17 (1.5) | 1.9 (0.83-4.51) | 1.9 (0.79-4.80) | ||||
| 0–4 | 405 (97.2) | 1,100 (98.5) | 1.0 (ref) | 1.0 (ref) | ||||
| ≥5 | 12 (2.8) | 17 (1.5) | 1.9 (0.91-4.05) | 2.0 (0.90-4.42)‡ | ||||
| Number of risk alleles* . | Cases . | Controls . | Crude OR (95% CI) . | OR (95% CI)† . | ||||
|---|---|---|---|---|---|---|---|---|
| 0 | 31 (7.4) | 85 (7.6) | 1.0 (ref) | 1.0 (ref) | ||||
| 1 | 117 (28.1) | 287 (25.7) | 1.1 (0.70-1.78) | 1.1 (0.69-1.85) | ||||
| 2 | 140 (33.6) | 368 (33.0) | 1.0 (0.66-1.64) | 1.0 (0.59-1.56) | ||||
| 3 | 87 (20.9) | 274 (24.5) | 0.9 (0.54-1.40) | 0.8 (0.51-1.41) | ||||
| 4 | 30 (7.2) | 86 (7.7) | 1.0 (0.53-1.72) | 1.0 (0.52-1.81) | ||||
| ≥5 | 12 (2.8) | 17 (1.5) | 1.9 (0.83-4.51) | 1.9 (0.79-4.80) | ||||
| 0–4 | 405 (97.2) | 1,100 (98.5) | 1.0 (ref) | 1.0 (ref) | ||||
| ≥5 | 12 (2.8) | 17 (1.5) | 1.9 (0.91-4.05) | 2.0 (0.90-4.42)‡ | ||||
NOTE: The subjects with six risk alleles were only two.
Risk alleles were defined as MnSOD C allele, CAT T allele, and GPX1 T allele reducing protection against ROS.
ORs adjusting for age at enrollment, history of prostate cancer in first-degree relative, random assignment, smoking status (current versus former or nonsmoker), pack-years smoked (<40, 40-60, ≥60), alcohol consumption (nondrinker, below median, at or above median) and vitamin supplement use in logistic regression model.
P = 0.091.